---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044598"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:25:42.150110+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics receives FDA Fast Track designation for LX2006 gene therapy for FA cardiomyopathy

## Summary
- FDA granted Fast Track designation for LX2006 (AAVrh.10hFXN gene therapy) for Friedreich's ataxia cardiomyopathy.
- LX2006 aims to deliver functional frataxin gene to restore mitochondrial function in myocardial cells.
- Phase 1/2 SUNRISE-FA trial ongoing to evaluate safety, tolerability, and preliminary efficacy in FA cardiomyopathy.
- LX2006 previously received Rare Pediatric Disease and Orphan Drug designations; Fast Track may accelerate development.
- FA cardiomyopathy is the leading cause of death among FA patients, with no approved treatments.

## SEC filing metadata
- accession: 0000950170-24-044598
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024044598/0000950170-24-044598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024044598/lxeo-20240416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044598
- JSON: https://secwatch.observer/filing/0000950170-24-044598.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.